Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) EBITDA Margin: 2019-2025

Historic EBITDA Margin for Keros Therapeutics (KROS) over the last 5 years, with Sep 2025 value amounting to -107.87%.

  • Keros Therapeutics' EBITDA Margin rose 1500992.00% to -107.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 17.67%, marking a year-over-year increase of 3135929.00%. This contributed to the annual value of -5,938.96% for FY2024, which is 10660475.00% up from last year.
  • Keros Therapeutics' EBITDA Margin amounted to -107.87% in Q3 2025, which was up 50.78% from -219.16% recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' EBITDA Margin registered a high of 2,019,700.00% during Q3 2021, and its lowest value of -541,000.00% during Q3 2023.
  • Over the past 3 years, Keros Therapeutics' median EBITDA Margin value was -15,117.78% (recorded in 2024), while the average stood at -87,260.48%.
  • Per our database at Business Quant, Keros Therapeutics' EBITDA Margin spiked by 142,230,000bps in 2021 and then slumped by 157,703,403bps in 2022.
  • Over the past 5 years, Keros Therapeutics' EBITDA Margin (Quarterly) stood at -24.33% in 2021, then slumped by 157,703,403bps to -134.03% in 2022, then reached -32,486.01% in 2023, then surged by 3,073,539bps to -1,750.62% in 2024, then soared by 1,500,992bps to -107.87% in 2025.
  • Its last three reported values are -107.87% in Q3 2025, -219.16% for Q2 2025, and 71.97% during Q1 2025.